Dare Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Dare Bioscience
DARE Stock  USD 2.42  0.02  0.83%   
Dare Bioscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dare Bioscience's valuation are provided below:
Gross Profit
-13.2 M
Market Capitalization
21.2 M
Enterprise Value Revenue
559.0176
Revenue
25.9 K
Earnings Share
(0.17)
There are over one hundred nineteen available fundamental signals for Dare Bioscience, which can be analyzed over time and compared to other ratios. Investors should ensure to verify all of Dare Bioscience's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of August 2, 2025, Market Cap is expected to decline to about 25.2 M. In addition to that, Enterprise Value is expected to decline to about 11.5 M

Dare Bioscience Total Revenue

9,294.8

Check Dare Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dare Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 40.2 K, Interest Expense of 528.6 M or Total Revenue of 9.3 K, as well as many indicators such as Price To Sales Ratio of 2.6 K, Dividend Yield of 0.19 or Days Sales Outstanding of 12.4 K. Dare financial statements analysis is a perfect complement when working with Dare Bioscience Valuation or Volatility modules.
  
Build AI portfolio with Dare Stock
Check out the analysis of Dare Bioscience Correlation against competitors.
For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.

Dare Bioscience Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.7 M22.1 M27.4 M
Very volatile
Short and Long Term Debt Total1.2 M1.3 M3.7 M
Slightly volatile
Other Current Liabilities3.9 M3.3 M3.5 M
Pretty Stable
Total Current Liabilities12.8 M21.6 M11.2 M
Slightly volatile
Property Plant And Equipment Net2.7 M2.5 M768.5 K
Slightly volatile
Accounts Payable1.5 M1.5 M1.4 M
Slightly volatile
Cash19.2 M15.7 M23.2 M
Very volatile
Non Current Assets Total3.8 M3.7 M1.6 M
Slightly volatile
Non Currrent Assets Other485.3 K810.6 K434.2 K
Slightly volatile
Cash And Short Term Investments19.2 M15.7 M23.2 M
Very volatile
Net Receivables218.5 K230 K778.3 K
Very volatile
Common Stock Shares Outstanding8.9 M8.5 M3.1 M
Slightly volatile
Liabilities And Stockholders Equity30.7 M22.1 M27.4 M
Very volatile
Non Current Liabilities Total7.6 M6.5 M8.9 M
Pretty Stable
Other Stockholder Equity178.4 B169.9 B21.8 B
Slightly volatile
Total Liabilities16.9 M28.1 M19.8 M
Very volatile
Total Current Assets21.1 M18.4 M25.4 M
Very volatile
Common Stock8268703 K
Slightly volatile
Current Deferred Revenue8.8 M16.6 M6 M
Slightly volatile
Property Plant And Equipment Gross2.9 M2.7 M755 K
Slightly volatile
Common Stock Total Equity5 K4.8 K2.6 K
Slightly volatile
Other Liabilities645.7 K1.1 M532.5 K
Slightly volatile
Capital Surpluse87.7 M63.3 M112.4 M
Slightly volatile
Other Current Assets2.7 M2.5 M2.2 M
Slightly volatile
Long Term Debt Total6.8 M4 M7.6 M
Slightly volatile
Capital Stock8268702.8 K
Slightly volatile
Capital Lease Obligations853.7 K1.3 M794.7 K
Pretty Stable

Dare Bioscience Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization40.2 K42.3 K300.4 K
Pretty Stable
Other Operating Expenses27.7 M23.5 M25 M
Slightly volatile
Research Development18.7 M14.2 M16.8 M
Slightly volatile
Total Operating Expenses27.2 M23.5 M24.5 M
Slightly volatile
Selling General Administrative8.7 M8.4 M7.8 M
Slightly volatile
Interest Income275.8 K290.4 K1.1 M
Slightly volatile
Reconciled Depreciation29.7 K42.3 K14.9 K
Slightly volatile
Selling And Marketing Expenses452.6 K800 K284.7 K
Slightly volatile

Dare Bioscience Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation40.2 K42.3 K129.9 K
Slightly volatile
Capital Expenditures601.7 K573 K225.2 K
Slightly volatile
End Period Cash Flow19.2 M16 M23.2 M
Very volatile
Stock Based Compensation1.4 M2.2 M1.2 M
Slightly volatile
Begin Period Cash Flow17.6 M10.8 M20.9 M
Very volatile
Change To Netincome1 M1.1 M2.6 M
Slightly volatile
Issuance Of Capital Stock430.9 K453.6 K12.8 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.6 K2.7 K17.5 K
Pretty Stable
Dividend Yield0.190.238.6976
Slightly volatile
Days Sales Outstanding12.4 K8.6 K5.1 K
Pretty Stable
Average Payables1.3 M2.2 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue23622536.7686
Slightly volatile
Capex To Depreciation14.2213.53924.055
Slightly volatile
Payables Turnover0.01240.0130.09
Slightly volatile
Sales General And Administrative To Revenue982.6 K935.8 K120 K
Slightly volatile
Research And Ddevelopement To Revenue1.5 K1.5 K309
Slightly volatile
Capex To Revenue61.558.56977.9645
Slightly volatile
Cash Per Share1.9 K1.8 K316
Slightly volatile
Days Payables Outstanding17.5 K29 K20.3 K
Slightly volatile
Intangibles To Total Assets0.290.330.3571
Slightly volatile
Current Ratio0.810.85373.1696
Slightly volatile
Receivables Turnover0.04040.04253.7174
Pretty Stable
Capex Per Share0.06410.06741.0339
Slightly volatile
Average Receivables612.5 K589.6 K454.4 K
Slightly volatile
Revenue Per Share0.00110.00122.961
Slightly volatile
Interest Debt Per Share0.150.153322.7631
Pretty Stable
Debt To Assets0.0560.0590.1704
Slightly volatile
Days Of Payables Outstanding17.5 K29 K20.3 K
Slightly volatile
Ebt Per Ebit18117323.0435
Slightly volatile
Quick Ratio0.810.853763.3216
Pretty Stable
Net Income Per E B T0.00110.00121.02
Slightly volatile
Cash Ratio0.690.72652.9386
Slightly volatile
Days Of Sales Outstanding12.4 K8.6 K5.1 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.10.89381.0056
Very volatile
Fixed Asset Turnover0.00370.00387.572
Slightly volatile
Debt Ratio0.0560.0590.1704
Slightly volatile
Price Sales Ratio2.6 K2.7 K17.5 K
Pretty Stable
Asset Turnover4.0E-44.0E-40.1011
Slightly volatile

Dare Bioscience Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap25.2 M26.5 M358.1 M
Slightly volatile

Dare Fundamental Market Drivers

Cash And Short Term Investments15.7 M

Dare Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Dare Bioscience Financial Statements

Dare Bioscience stakeholders use historical fundamental indicators, such as Dare Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Dare Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Dare Bioscience's assets and liabilities are reflected in the revenues and expenses on Dare Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Dare Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue16.6 M8.8 M
Total Revenue9.8 K9.3 K
Cost Of Revenue513.3 K539 K
Stock Based Compensation To Revenue 225.19  236.45 
Sales General And Administrative To Revenue935.8 K982.6 K
Research And Ddevelopement To Revenue1.5 K1.5 K
Capex To Revenue 58.57  61.50 
Ebit Per Revenue-2.4 K-2.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
When determining whether Dare Bioscience is a strong investment it is important to analyze Dare Bioscience's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Dare Bioscience's future performance. For an informed investment choice regarding Dare Stock, refer to the following important reports:
How To Invest In Dare
Details
Is Dare Stock a good investment?
Details
What is Dare Bioscience's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Dare Bioscience Correlation against competitors.
For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dare Bioscience. If investors know Dare will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dare Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.17)
Revenue Per Share
0.003
Quarterly Revenue Growth
1.734
Return On Assets
(0.87)
Return On Equity
(9.95)
The market value of Dare Bioscience is measured differently than its book value, which is the value of Dare that is recorded on the company's balance sheet. Investors also form their own opinion of Dare Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Dare Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dare Bioscience's market value can be influenced by many factors that don't directly affect Dare Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Dare Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dare Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dare Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY